CLOPIDOGREL-RESISTANCE
(CYP2C19 GENE TEST)
Background
Clopidogrel (Plavix) inhibits platelet aggregation and is used in the management of patients with coronary artery disease, with acute coronary syndromes, and/or after percutaneous coronary interventions. Clopidogrel is an inactive pro-drug that requires hepatic activation cytochrome P450 2C19 (CYP2C19).
CYP2C19 genotypes
Genotype | Genotype | Frequency | Commentary |
*1*1 | Extensive metabolizer | 71% | No sign of reduced CYP2C19 activity. |
*1*2, *1*3 | Intermediate metablizer | 26% | Reduced CYP2C19 activity. Reduced effectiveness of clopidogrel. |
*2*2, *2*3, *3*3 | Poor metabolizer | 3% | Strongly reduced CYP2C19 activity. Reduced effectiveness of clopidogrel. |
Indications for testing
Literatur:
-
New Genetic Tests
- Clopidogrel Resistance (CYP2C19)
- Statin Side-Effects (SLCO1B1)
- Morbus Wilson (ATP7B)